QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires
Key Points
A board director at QuidelOrtho Corp. acquired 10,000 common shares on Feb. 13, 2026, at an average price of around $23.96 per share, totaling ~$240,000.
All shares were acquired for direct ownership; indirect holdings via UGMA accounts and Birchview Fund, LLC, remain unchanged at 54,775 shares.
- 10 stocks we like better than QuidelOrtho ›
Matthew Strobeck, a Board Director at QuidelOrtho Corp. (NASDAQ:QDEL), reported the purchase of 10,000 common shares on Feb. 13, 2026, for a total transaction value of ~$240,000, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded | 10,000 |
| Transaction value | $239,586.00 |
| Post-transaction shares (direct) | 27,775 |
| Post-transaction value (direct ownership) | $655,000 |
Transaction value based on SEC Form 4 reported price ($23.96); post-transaction value based on Feb. 13, 2026 market close ($23.58).
Key questions
- What proportion of Matthew Strobeck’s ownership was affected by this purchase?
This acquisition represented 13.78% of his total reported holdings and 56.26% of his direct stake. - What is the structure of Strobeck’s post-transaction holdings?
After the trade, Strobeck holds 27,775 shares directly and 54,775 shares indirectly through UGMA accounts and Birchview Fund, LLC, with total beneficial ownership of approximately 82,550 shares.
Company overview
| Metric | Value |
|---|---|
| Price | $22.74 |
| Revenue (TTM) | $2.73B |
| Net Loss (TTM) | $1.13B |
| 1-year price change | -44.37% |
*Price and 1-year performance calculated using Feb. 28, 2026 as the reference date.
Company snapshot
QuidelOrtho Corporation is a global diagnostics testing solutions company with a broad portfolio spanning laboratory, transfusion medicine, point-of-care, and molecular testing platforms. Its client base includes healthcare providers, laboratories, blood banks, donor centers, and retail channels globally.
What this transaction means for investors
Only two years after QuidelOrtho fired its previous President and CEO and substantial workforce layoffs, the pharmaceutical company is still recovering from its structural changes. Share prices have been down for five consecutive years and have fallen ~23% so far in 2026 (as of Feb. 28). And now, the company has to replace yet another major executive, after current CFO Joseph M. Busky, announced his retirement, and QuidelOrtho has until June to find his replacement, as that’s when the retirement goes into effect.
QuidelOrtho reported its Q4 FY 2025 earnings on Feb. 11, and it closed the fiscal year with a 1.89% year-over-year (YoY) decline in revenue, marking the third straight year of declining annual revenue.
It also marked the third straight year of operating at a net loss and with negative earnings per share (EPS). With years of consistent financial and stock declines, QuidelOrtho is one of the less appealing stocks in the pharmaceutical market.
Should you buy stock in QuidelOrtho right now?
Before you buy stock in QuidelOrtho, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and QuidelOrtho wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $519,015!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,086,211!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 1, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends QuidelOrtho. The Motley Fool has a disclosure policy.
Recommended Articles
